

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Urinary proteome and metabolome in dogs (Canis lupus familiaris): The effect of chronic kidney disease

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Ferlizza, E., Isani, G., Dondi, F., Andreani, G., Vasylyeva, K., Bellei, E., et al. (2020). Urinary proteome and metabolome in dogs (Canis lupus familiaris): The effect of chronic kidney disease. JOURNAL OF PROTEOMICS, 222, 1-12 [10.1016/j.jprot.2020.103795].

Availability:

This version is available at: <https://hdl.handle.net/11585/760657> since: 2020-05-31

Published:

DOI: <http://doi.org/10.1016/j.jprot.2020.103795>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

Urinary proteome and metabolome in dogs (*Canis lupus familiaris*): the effect of chronic kidney disease

E. Ferlizza^a, G. Isani^{b,*}, F. Dondi^b, G. Andreani^b, K. Vasylyeva^b, E. Bellei^c, A.M. Almeida^d, M. Matzapetakis^e

^a *Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy*

^b *Department of Veterinary Medical Sciences, University of Bologna, Ozzano, Bologna, Italy.*

^c *Department of Surgery, Medicine, Dentistry and Morphological Science with Transplant Surgery, Oncology and Regenerative Medicine Relevance, Proteomic Lab, University of Modena and Reggio Emilia, Modena, Italy*

^d *LEAF, Insitituto Superior de Agronomia, Universidade de Lisboa, Lisboa, Portugal*

^e *ITQB/UNL – Chemical and Biological Technologies Institute of the New University of Lisbon, Oeiras, Portugal*

* Corresponding author.

Gloria Isani, E-mail address: gloria.isani@unibo.it

Department of Veterinary Medical Sciences

University of Bologna

Via Tolara di sopra, 50

40064 Ozzano Emilia (BO)

Tel. 051 20 97019

26 **Abstract:**

27 Chronic kidney disease (CKD) is a progressive and irreversible disease. Although urine is an ideal
28 biological sample for proteomics and metabolomics studies, sensitive and specific biomarkers are
29 currently lacking in dogs. This study characterised dog urine proteome and metabolome aiming to
30 identify and possibly quantify putative biomarkers of CKD in dogs. Twenty-two healthy dogs and 28
31 dogs with spontaneous CKD were selected and urine samples were collected. Urinary proteome was
32 separated by SDS-PAGE and analysed by mass spectrometry, while urinary metabolome was
33 analysed in protein-depleted samples by 1D ^1H NMR spectra. The most abundant proteins in urine
34 samples from healthy dogs were uromodulin, albumin and, in entire male dogs, arginine esterase. In
35 urine samples from CKD dogs, the concentrations of uromodulin and albumin were significantly
36 lower and higher, respectively, than in healthy dogs. In addition, these samples were characterised by
37 a more complex protein pattern indicating mixed glomerular (protein bands $\geq 65\text{kDa}$) and tubular
38 (protein bands $< 65\text{kDa}$) proteinuria. Urine spectra acquired by NMR allowed the identification of 86
39 metabolites in healthy dogs, belonging to 49 different pathways mainly involved in amino acid
40 metabolism, purine and aminoacyl-tRNA biosynthesis or tricarboxylic acid cycle. Seventeen
41 metabolites showed significantly different concentrations when comparing healthy and CKD dogs.
42 In particular, carnosine, trigonelline, and cis-aconitate, might be suggested as putative biomarkers of
43 CKD in dogs.

44
45 **Significance:** Urine is an ideal biological sample, however few proteomics and metabolomics studies
46 investigated this fluid in dogs and in the context of CKD (chronic kidney disease). In this research,
47 applying a multi-omics approach, new insights were gained regarding the molecular changes
48 triggered by this disease in canine urinary proteome and metabolome. In particular, the involvement
49 of the tubular component was highlighted, suggesting uromodulin, trigonelline and carnosine as
50 possible biomarkers of CKD in dogs.

52 **Introduction**

53 Chronic kidney disease (CKD) is a progressive and irreversible disease characterised by the presence
54 of structural or functional abnormalities in one or both kidneys over a period of three months or longer
55 [1]. CKD is one of the most common renal diseases in dogs with an estimated prevalence varying
56 from 0.5 to 3.64% depending on the inclusion criteria of the cases [1–3]. Early diagnosis of CKD
57 may hinder the disease progression and improve patient quality of life. International Renal Interest
58 Society (IRIS) guidelines for staging and treatment of CKD help clinicians to correctly classify
59 patients and establish the best therapies [4]. Nonetheless, sensitive and specific biomarkers for early
60 detection and monitoring of CKD in dogs are currently lacking. The gold standard to evaluate the
61 renal function is the determination of the glomerular filtration rate (GFR); however, this value does
62 not provide information on CKD aetiology and the available methods for its estimation are difficult
63 to be applied in the routine clinical practice [5,6]. Renal biopsy is considered the gold standard for
64 determining the type of renal damage, but it is an invasive procedure and not always feasible [7].
65 Therefore, the assessment of the kidney function is currently based on conventional blood (serum
66 creatinine or urea) and urine (proteinuria and specific gravity) clinicopathological variables, whose
67 alterations are usual findings of CKD but have limitations when used as early indicators of the disease
68 [7]. For these reasons, other sensitive and specific biomarkers measurable in non- or minimally
69 invasive biological samples are required in clinical practice to identify early renal damage in dogs.
70 Over the last years, significant efforts have been made in veterinary medicine to apply proteomics to
71 search for new biomarkers or for validating detection methods for proteins already considered as
72 potential early indicators of kidney disease in dogs and cats [8–17]. However, proteins are only some
73 of the molecular species present in urine and a broader approach with the aid of metabolomics can
74 offer additional clinical information.
75 Metabolomics enables the assessment of a broad range of endogenous and exogenous small molecular
76 mass metabolites, potentially useful to investigate the physiologic status and the pathogenesis of the
77 diseases, and to discover new biomarkers of altered biochemical pathways [18–21]. Metabolites are

78 in general not specific for a single metabolic pathway and in most cases different biochemical
79 reactions contribute to the production of the same metabolite; this peculiarity offers the opportunity
80 to obtain a more comprehensive insight into the complexity of a biological sample. In human
81 medicine, metabolomics was extensively applied to urine to analyse the healthy metabolome [22] and
82 to search for small molecules as potential biomarkers of different diseases, such as immune-mediated
83 inflammatory diseases [23], different cancers [24–26], and renal diseases [19,27–30]. However, in
84 veterinary medicine, the application of metabolomics techniques to urine is still limited [31–35].
85 Owing to the metabolic and protein complexity of urine, the aim of this work was to combine the
86 analytical power of proteomics and metabolomics to obtain a more comprehensive characterisation
87 of the urine in healthy dogs and to compare it with the urine from CKD patients with our ultimate
88 goal to suggest new biomarkers of CKD in the canine species.

89

90 **Materials and Methods**

91 *Animal selection and sample collection*

92 The present study was performed on urine samples collected at the Veterinary Teaching
93 Hospital of the University of Bologna from owned dogs. The dogs were divided into two experimental
94 groups and specimens considered as biological replicates. Upon arrival, all dogs were subjected to
95 physical examination and routine laboratory tests, including complete blood count, serum chemistry
96 and complete urinalysis with urine protein to creatinine ratio (UPC).

97 Blood samples were collected by venepuncture using a vacuum collection system (Vacutest
98 Kima, Arzergrande, Italy) after at least a 12-hour fasting period. Blood samples were processed within
99 one hour after collection. Serum samples were collected in tubes with clot activator (Vacutest Kima,
100 Arzergrande, Italy), centrifuged at 3,000 g for 10 minutes and analysed in an automated chemistry
101 analysed (AU 480, Olympus/Beckman Coulter, Atlanta, GE, USA).

102 Urine samples were collected by ultrasound-guided cystocentesis. All urine specimens were
103 processed on a routine basis and evaluated in our laboratory within two hours after collection. In

104 particular, urinalysis consisted in macroscopic examination, urine specific gravity (USG) measured
105 by manual refractometer (American Optical, Buffalo, New York), urine dipstick test (Combur10Test,
106 Roche Diagnostic, Mannheim, Germany) applied on an automated readers (Urisys 1100, Roche
107 Diagnostic, Mannheim, Germany, respectively) and microscopic sediment evaluation. Urine
108 sediment was obtained after centrifugation at 500 g for 10 minutes. Urine supernatants were
109 immediately analysed (dipstick examination), divided in aliquots and stored at -80°C for the
110 subsequent proteomics and metabolomics analysis. Urine chemistry was performed on a refrigerated
111 ($+4^{\circ}\text{C}$) aliquot if performed within 24 hours after the sample processing or on an aliquot kept frozen
112 at -20°C for a maximum of 7 days.

113 Dogs were considered healthy or diseased on the basis of history, clinical signs and the results
114 of the above-mentioned routine laboratory tests. The control group included 22 healthy dogs
115 presented at the hospital as blood donors. The 22 healthy dogs were 10 males (3 castrated) and 12
116 females (7 spayed) with an average age of 37 ± 20 months. The diseased group included 28 dogs
117 affected by naturally occurring CKD. The 28 CKD dogs were 14 males (5 castrated) and 14 females
118 (9 spayed) with a mean age of 111 ± 61 months. The diagnosis of CKD based on history, clinical signs,
119 clinicopathological and imaging results, according to the literature [3,4]. In particular, the presence
120 of clinical findings, abdominal imaging results and (a) persistent pathologic renal proteinuria based
121 on the UPC ($\text{UPC}>0.5$), assessed and confirmed over a one-month period, and/or (b) serum creatinine
122 (sCrea) concentration ≥ 1.40 mg/dL and/or (c) urine specific gravity (USG) <1.030 were considered
123 diagnostic. The IRIS CKD guidelines were used to subsequently stage CKD dogs [4]. Basing on
124 serum creatinine, 8 dogs were classified with CKD stage 1, 6 with stage 2, 9 with stage 3 and 5 with
125 stage 4. On the basis of UPC, 4 dogs were non-proteinuric ($\text{UPC}<0.2$), 6 dogs were borderline
126 proteinuric ($\text{UPC } 0.2\text{-}0.5$) and 18 were proteinuric ($\text{UPC}>0.5$).

127 The study was conducted according to the EU Directive 2010/63/EU for animal experiments
128 and approved by the Institutional Scientific Ethical Committee of the University of Bologna for
129 animal testing.

130 *Urine protein to creatinine ratio*

131 Five mL of urine were collected from each animal by ultrasound-guided cystocentesis. After
132 centrifugation at 500 g for ten minutes, urine total proteins and creatinine were measured using
133 commercial kits (Urinary/CSF Protein, OSR6170, and Creatinine OSR6178, Olympus/Beckman
134 Coulter, Atlanta, GE, USA) on an automated chemistry analyser (AU 480, Olympus/Beckman
135 Coulter, Atlanta, GE, USA). The UPC was calculated with the following formula: UPC = urine
136 protein (mg/dL)/urine creatinine (mg/dL).

137

138 *SDS-PAGE and protein identification*

139 Urine proteins were separated using an electrophoresis system (NuPAGE, Thermo Fisher
140 Scientific, Waltham, MA, USA) as previously described [8,36]. Briefly, three to five µg of protein
141 were loaded on 4-12% polyacrylamide gel in MOPS buffer with SDS (Thermo Fisher Scientific,
142 Waltham, MA, USA). The gels were stained with Coomassie brilliant blue (PageBlu protein staining
143 solution; Thermo Fisher Scientific, Waltham, MA, USA) compatible with mass spectrometry
144 analysis. After staining, each gel was digitalized (ChemidocMP, BioRad, Hercules, California, USA)
145 and the pherograms were obtained using a commercial software (ImageLab, BioRad, Hercules,
146 California, USA). The bands at 100, 67 and 18 kDa were cut and identified by electrospray ionization
147 quadrupole time-of-flight mass spectrometry (ESI-Q-TOF/MS) as previously reported [8,36].

148 To quantify the bands at 100 kDa and 67 kDa, on each sample, one µg of protein, obtained from a
149 solution containing 1 µg/µL of lactate dehydrogenase (LDH), (Sigma-Aldrich/Merck KGaA,
150 Darmstadt, Germany) was added as internal standard of quantity. The ImageLab software estimated
151 the volume of each protein band based on pixel density within the band boundaries in the digital
152 image. The volume of the band of interest was then compared to the internal standard (LDH) of the
153 corresponding lane and the concentration was calculated as follows:

154
$$X \text{ mg/dL} = (V_{\text{band}}/V_{\text{LDH}}) / \mu\text{L}_{\text{sample}} * 100.$$

155 X = concentration of the protein at 100 kDa or at 67 kDa

156 V_{band} = volume of the band at 100 kDa, or at 67 kDa determined by the software
157 V_{LDH} = volume of the band of the internal standard (LDH) determined by the software
158 $\mu\text{L}_{\text{sample}}$ = μL of the sample loaded in the gel
159 Subsequently, the respective ratios with urine creatinine (uromodulin [mg]: creatinine [mg], UMC;
160 albumin [mg]: creatinine [mg], UAC) were calculated.

161

162 *NMR Sample preparation*

163 Urine metabolites were extracted for NMR as follows: 500 μl of urine supernatants were mixed with
164 550 μl of chloroform and 550 μl of methanol, vortexed for 1 min, left to rest for 15 min at +4°C and
165 centrifuged at 12,000 g for 15 min at room temperature. Nine hundred μl of the upper phase
166 (urine/methanol) were dried in a vacuum centrifuge (SpeedVac, Thermo Fischer Scientific, Waltham,
167 MA, USA) overnight at 30°C. The resulting pellets were suspended with 200 μl of phosphate buffer
168 (PB, 240 mM pH 7.4 in D_2O with trimethylsilylpropanoic acid [TSP] and sodium azide [NaN_3]) and
169 400 μl of D_2O to a final concentration of 80 mM PB, 0.087 mM TSP and 0.022% (v/v) NaN_3 . Samples
170 were vortexed for 1 min, centrifuged at 12,000 g for 1 min and 560 μl transferred into a 5 mm NMR
171 tubes.

172

173 *NMR acquisition*

174 NMR spectroscopy was conducted on an 800 MHz spectrometer with a triple resonance HCN Z-
175 gradient probe, at 298 K (Bruker AvanceII+, Ettlingen, Germany). Acquisition and processing were
176 carried out using standard software (Topsin 3.2, Bruker Biospin, Billerica, MA, USA). One
177 dimensional ^1H NMR spectra with Carr-Purcell-Meiboom-Gill (CPMG) filter to attenuate signals
178 from macromolecules were acquired using a standard vendor pulse sequence (cpmgpr1d). Spectra
179 were acquired at 25°C, with a 20 ppm spectral width, spin lock duration of 78.72 ms, presaturation
180 for 4 s using 20 μW and acquisition time of 2 s. A total of 16 dummy scans and 128 scans were
181 acquired for each sample. All spectra were processed with an exponential window function with 1

182 Hz line broadening and automated phasing and baseline correction. For the chemometric analysis,
183 the processed data were further processed in the “nmrprocflow” platform [37]. Bins were obtained
184 using manually curated, intelligent binning after referencing, baseline correction, water signal
185 removal and peak alignment. For selected samples, additional homonuclear and heteronuclear spectra
186 (¹H J-resolved, ¹H-¹H COSY, and ¹H-¹³C HSQC) were also collected to assist with compound
187 identification.

188

189 *Metabolite annotation and identification*

190 The bins obtained from the “nmrprocflow” platform [37] were annotated with the help of database
191 assisted spectral decomposition using commercial software (Chenomx 8.2 NMR Suit, Edmonton,
192 Alberta, Canada) and the internal reference library (Version 10) as well as the Biological Magnetic
193 Resonance Data Bank (BMRB, <http://www.bmrwisc.edu>) reference spectra for compounds absent
194 in the internal reference library. Buckets were attributed to multiple metabolites where peaks were
195 found to overlap. Pathway analysis module of a free web-based analytical platform (Metaboanalyst
196 4.0, www.metaboanalyst.ca), that used the high-quality Kyoto encyclopaedia of genes and genomes
197 (KEGG) metabolic pathways as the backend knowledgebase, was used to search for the metabolic
198 pathways.

199

200 *Statistical analysis*

201 Serum and urine chemistry data were analysed with statistical software (R version 3.4.4). Normal
202 distribution was tested graphically and by Shapiro-Wilk normality test, and data were expressed as
203 mean ± standard deviation (SD) or median (range; minimum – maximum value) if normally or non-
204 normally distributed, respectively. Variables were compared between healthy (N=22) and CKD
205 (N=28) dogs using the Student t-test or the Mann-Whitney U test depending on their distribution,
206 assuming $P < 0.05$ as a significant probability. The Kruskal-Wallis rank sum test was applied to
207 evaluate differences among healthy and CKD stages (stages 1-4, basing on serum creatinine and

208 according to the IRIS guidelines [4]) and adjusted *P*-values lower than 0.05 were considered
209 statistically significant.

210 For metabolomics statistical analysis, processed spectra were aligned, baseline corrected and divided
211 into 397 variable width spectral regions or ‘buckets’ with the intensity of each bucket divided by the
212 bucket width. To identify the signals differentially present in the two groups, the buckets were loaded
213 into a web-based platform (Metaboanalyst 4.0, www.metaboanalyst.ca) which uses the R package of
214 statistical computing software [38]. For multivariate analysis, buckets were scaled by auto scaling
215 (mean-centred and divided by the standard deviation of each variable) while, for univariate analysis,
216 and in order to remove the influences attributed to muscle mass and urine concentration, the bucket
217 intensities were normalised to the peak of creatinine (bucket 3.0360 ppm). Both univariate and
218 multivariate statistics were employed. t-test and fold change analysis were used to identify the buckets
219 with differential presence, while the list was supplemented with the use of unsupervised principal
220 components analysis (PCA) and supervised partial least squares discriminant analysis (PLS-DA).
221 Both PCA and PLS-DA can identify signals (buckets) whose importance becomes significant via
222 correlated variance. In addition, PCA provides a global view of the differentiability between the two
223 experimental conditions and the groups of observables that are mostly responsible. In contrast, PLS-
224 DA, since it is a supervised method, highlights the variables most responsible for the differences
225 between groups as previously used in other metabolomics approaches [39,40]. The small sample size
226 that is typical in such studies and the inherent large number of variables obtained may affect the
227 consistency of the multivariate analysis used. To evaluate the consistency of the results, the software
228 performs a number of tests and reports the parameters Q^2 and R^2 as quality parameters of the models.
229 Q^2 indicates the predictive ability of the model, while R^2 is the indicator of the suitability of the fit.
230 For PLS-DA $Q^2 > 0.6$ were selected as acceptable models. Variable importance in projection (VIP)
231 scores greater than 1 and t-test with a *P* value < 0.05 were used to identify metabolites as differentially
232 expressed.

233

234 Results

235 Clinical data

236 Mean clinical data, serum and urine biochemistry of healthy and CKD dogs are reported in Table 1,
237 while the results for each dog are reported in Supplement Table 1.

238 CKD dogs were significantly older ($P<0.0001$), had significantly higher concentration of serum
239 creatinine ($P<0.0001$), urea ($P<0.0001$) and UPC ($P<0.0001$), while USG ($P<0.0001$) was
240 significantly lower than in the healthy dogs. CKD patients were also staged according to serum
241 creatinine concentration following IRIS guidelines [4] and the differences of UPC and USG were
242 evaluated. USG was significantly lower in each CKD stage group than in the healthy dogs ($P<0.01$),
243 and samples classified as CKD stage 1 had higher USG than those classified as Stage 3 ($P=0.016$)
244 and 4 ($P=0.007$). UPC was significantly higher in each CKD stage groups than in healthy dogs
245 ($P<0.05$), however, no significant differences were found among CKD stages.

246

247 SDS-PAGE Proteomics Analysis

248 Representative gels and pherograms from healthy and CKD dog urines are reported in Fig. 1.

249 Urine samples from the healthy group presented similar profiles characterised by the presence of three
250 most abundant bands at apparent molecular mass (MM) of 103, 80 and 67 kDa, respectively. The
251 bands at 103 and 67 kDa were identified by mass spectrometry as uromodulin and albumin
252 respectively (Table 2). Moreover, most of the samples presented other three to five low abundance
253 bands at apparent MM between 55 and 14 kDa and two bands at MM < 14 kDa. In addition, urine
254 samples from entire males presented other two evident bands at apparent MM of 18 and 12 kDa. The
255 band at 18 kDa was identified as arginine esterase (Table 2).

256 CKD samples presented different and more variable electrophoretic profiles. The disappearance of
257 uromodulin and/or the increase of intensity of albumin and of the band at 80 kDa were clearly evident
258 in all the analysed samples. The increase in number and intensity of the bands at high (>67 kDa) and
259 low (<67 kDa) MM was also evidenced. Particularly, two samples presented an increase in number

260 and intensity of the bands at high (>67 kDa) MM only, nine samples showed an increase in number
261 and intensity of the bands at low (<67 kDa) MM only, while the remaining 17 samples presented an
262 increase in number and intensity of the bands at both high and low MM. Additionally, in 12 samples
263 (Fig. 1; Lanes 1, 3, 5, 8) was evidenced a band at 21 kDa that was not present in healthy samples.
264 Concentrations of uromodulin and albumin and their ratio with creatinine (UMC and UAC) are
265 reported in Table 3. Urine samples from healthy dogs presented **a** low amount of albumin (3.1 ± 1.4
266 mg/dL) and **a** high amount of uromodulin (11.9 ± 2.3 mg/dL). CKD dogs presented **a** significantly
267 higher concentration of albumin ($P=0.0025$) and UAC value ($P=0.0002$) and **a** significantly lower
268 concentration of uromodulin ($P<0.0001$) and UMC value ($P=0.0044$), compared to healthy animals.

269

270 *Metabolites annotation and identification*

271 Representative NMR spectra from healthy and CKD dog urine samples are reported in Fig. 2.
272 An overview of the NMR spectra of samples from healthy dogs evidenced similar profiles, while the
273 urine from CKD patients showed more variable spectra and differences in **metabolite** abundance.
274 From the 397 buckets, 86 metabolites were identified **in healthy samples**, with different biological
275 functions and belonging to different pathways. An entire spectrum of the urine of a healthy dog with
276 the assigned metabolites **is reported in Fig. 3**. The five most abundant metabolites were creatinine,
277 urea, taurine, lactate and 1-methylnicotinamide, while the list of all the identified metabolites is
278 reported in Table 4. After MetaboAnalyst pathway analysis, metabolites were shown **as belonging** to
279 49 different pathways, and 23 of these pathways were represented by at least 3 different metabolites.
280 The most represented pathways are mainly involved in amino acid metabolism, purine and
281 aminoacyl-tRNA biosynthesis and tricarboxylic acid cycle (Table 5). In particular, 10 metabolites
282 belonged to glycine, serine and threonine metabolism and aminoacyl-tRNA biosynthesis, while 8
283 metabolites were involved in phenylalanine metabolism and purine metabolism.
284 By univariate T-test, 83 buckets resulted significantly different between healthy and CKD dog urine
285 samples. Unsupervised multivariate analysis (PCA) was able to distinguish between healthy and CKD

286 dogs (Fig. 4). The supervised multivariate analysis using PLS-DA (Fig. 4, Table 6) indicated that the
287 optimal model comprised 5 components ($R^2=0.99$, $Q^2=0.74$), but also the model with only one
288 component had reasonable predictive value ($R^2=0.73$, $Q^2=0.62$). Both univariate and multivariate
289 analysis were used to identify the differentially abundant metabolites. Of the 83 significantly different
290 buckets, 21 were assigned to 17 metabolites (Table 6). The metabolites showing the highest increase
291 in CKD samples were carnosine, 7-methylxanthine and cis-aconitic acid, while the metabolites
292 showing the most evident decrease were trigonelline and urocanic acid.

293

294 Discussion

295 The aim of the present research was to characterise the urinary proteome and metabolome in healthy
296 dogs and to compare it with that of urine collected from CKD patients to suggest biomarkers of the
297 disease that would be useful in veterinary medicine.

298 In the present study, SDS-PAGE allowed the separation of the urinary proteins based on their
299 molecular mass giving information about the localisation of the nephron damage. Most urine samples
300 (17/28) of CKD dogs analysed in this study had protein bands at either high and low MM, indicating
301 a mixed glomerular and tubular pattern. It is generally recognised that the renal proteinuria with an
302 UPC>2 is strongly indicative of glomerular involvement [41,42]. Our data support this evidence, as
303 the electrophoretic profiles of the seven urine samples with an UPC>2 were characterized by protein
304 bands with high MM. However, in all these samples, bands with low MM were also present,
305 suggesting a concomitant tubular damage. Other authors reported a tubular impairment in dogs with
306 UPC>2 [42,43]. On the other hand, in our study, 7 of the 21 samples with UPC<2 indicated also a
307 glomerular involvement and hence the evaluation of proteinuria by UPC could lead to
308 misinterpretation regarding the nephronal origin of the proteinuria, as previously suggested by other
309 authors [41,43–46].

310 In the present study, 8 dogs with early stages of CKD (I and II; serum creatinine <2.1 mg/dL),
311 classified as non-proteinuric (UPC<0.2) or borderline proteinuric (UPC 0.2-0.5), showed altered

312 electrophoretic profiles with the decrease of uromodulin and the increase in number and intensity of
313 low MM bands. Chacar et al., [43] also reported the prevalence of tubular pattern in urine samples of
314 dogs with early stages of CKD. On the other hand, out of 14 dogs affected by CKD at advanced IRIS
315 stages (III and IV; serum creatinine >2.1 mg/dL), 10 patients had a mixed profile while 4 dogs
316 presented a clear tubular pattern, with absent or mild glomerular involvement. Tubular epithelium
317 seems to be more susceptible to ongoing stress and dysregulation promoting interstitial inflammation
318 and fibrosis [47]. Therefore, it can be hypothesized that, in general, dogs with CKD in the initial
319 phases (serum creatinine < 2.1 mg/dL and UPC < 0.5) might present a prevalent tubulointerstitial
320 involvement followed by a gradual glomerular impairment leading to an increase of albumin and
321 higher MM proteins in urine. In this complex scenario, the analysis of qualitative proteinuria could
322 be essential to better characterise the kidney damage and the nephronal involvement.

323 In addition to the evaluation of the electrophoretic protein profiles, SDS-PAGE allowed the
324 quantification of urinary uromodulin and albumin. In urine samples of healthy dogs, the abundance
325 of uromodulin associated with the low concentration of albumin is confirmatory of data previously
326 reported by other authors [43,48–50]. In our study, the quantification of these two proteins, followed
327 by UMC and UAC calculation, represents an additional step for their clinical use. In fact, uromodulin
328 and albumin are known markers of renal dysfunction or damage, in particular of CKD [51,52]. Raila
329 et al., [50] reported a decrease of uromodulin in azotaemic and proteinuric dogs affected by renal
330 disease and, despite the different method used for protein quantification (western blot), UMC values
331 determined in the healthy dogs were comparable to our results. In addition, Chacar et al., [43]
332 quantified uromodulin by western blotting and reported a decrease of uromodulin only in the late
333 stages of CKD (IRIS 3-4), suggesting this protein as a marker of CKD progression rather than of early
334 diagnosis. Differently, in the present study, the decrease of uromodulin was observed by SDS-PAGE
335 already in stage 1 non-proteinuric CKD dogs, suggesting uromodulin as a promising and early
336 biomarker of renal dysfunction in dogs.

337 Urinary albumin concentration is low in healthy dogs and an increase occurs in the presence of renal
338 involvement [11,53]. Accordingly, in the present study, healthy dogs have low values of albumin and
339 UAC, in the range of those reported by other authors [11,54–57]. Different authors determined
340 albuminuria in dogs affected by a variety of diseases and conditions, including CKD [11,53–56,58–
341 62]. However, despite the clinical importance of albumin quantification in urine, the reference
342 intervals for albuminuria are still lacking for dogs and should be the aim of further research.

343 Finally, the presence of arginine esterase in urine of entire male dogs was also evidenced and needs
344 to be considered to correctly interpret urine electrophoretic profile and to exclude false tubular
345 involvement as previously reported [15,42].

346 The second part of the study focused on the application of NMR to characterise the urinary
347 metabolome of healthy dogs and to evaluate the differences with CKD patients. As most CKD
348 samples contained high protein concentrations, to avoid interferences on NMR spectra and possible
349 false positives, a further step in sample preparation was added by precipitating the proteins. This step
350 allowed the enrichment of urine metabolome, improving the quality of the spectra and the
351 identification of a higher number of metabolites. Moreover, since the high repeatability of NMR
352 metabolomics is well known [20,21], no technical replicates were analysed and only biological
353 replicates were considered. From the corresponding spectra, 86 metabolites were identified in healthy
354 samples, a number higher than those previously reported in dog urine by other authors [32,33,63,64]
355 and producing, so far and to the best of our knowledge, one of the most complete dataset of canine
356 urinary metabolome. Most of these metabolites are of endogenous origin, while others, like ferulic
357 acid, are of exogenous or mixed origin. Most of the identified metabolites were previously reported
358 in urine of healthy or diseased dogs [32,33,65], in human urine [19,22] and also in feline urine [31].

359 The majority of these metabolites is involved in amino acids metabolism, purine and pyrimidine
360 metabolism, tricarboxylic acid cycle and methane metabolism. Nine metabolites were significantly
361 increased in urine of CKD dogs. Carnosine, a dipeptide composed by alanine and histidine acting as
362 an antioxidant scavenger, showed the most evident increase. This molecule is filtered by the

glomerulus and then reabsorbed at the level of the proximal tubule by the proton-coupled oligotransporter PEPT2 [66]. It has been recently reported that the kidney has an intrinsic carnosine metabolism with carnosine synthase and carnosinase 1 activity in the glomeruli and tubular cells [67,68]. In CKD dogs, the increased urinary excretion of carnosine may reflect an oxidative stress suffered by the kidney, a condition hypothesised also by other authors in obese dogs [32,65]. Moreover, since carnosine is present at high concentrations in muscle tissues, and muscle weakness and atrophy are common findings in CKD patients, the increase of this molecule in urine may also reflect an increased muscle catabolism [65]. Finally, as a causative event, a damage of the epithelium of the proximal tubule might also be hypothesised, leading to impaired reabsorption of carnosine; this hypothesis is supported by the decrease of uromodulin evidenced by SDS-PAGE and by the increase of cis-aconitic acid in urine of CKD dogs. Cis-aconitic acid, an intermediate in the tricarboxylic acid cycle, was observed in the urine of type 2 diabetic human patients. In fact, increased excretion of this metabolite reflects local effects on tubular transport in the kidneys [69]. Therefore, a damage of the tubular epithelium might determine an inefficient reabsorption leading to an increased concentration of urinary cis-aconitic acid and carnosine.

Regarding other urinary metabolites increased in urine of CKD dogs, xanthosine, allantoin, and 7-methylxanthine are of interest. These metabolites belong to the complex pathways of purine metabolism; in particular, during purine catabolism, the nucleoside xanthosine is transformed into xanthine, which in turn is oxidized to uric acid by uricase. In humans, uric acid is the end product of purine catabolism, while in dogs an additional reaction transforms this metabolite into allantoin. In humans, some of these metabolites were suggested as possible markers of diabetic nephropathy [70], end stage renal disease [71] or other kidney disorders [72], while an increase of allantoin and xanthine to creatinine ratios were previously reported in urine of dogs affected by CKD [73]. Despite the possible influence of medications, such as allopurinol or diuretics received by two CKD dogs included in the present study, that could have affected purine metabolism, these data show evidence

388 that CKD is associated with alterations in urinary concentrations of purine metabolites, and thus, this
389 issue deserves more attention in further research.

390 Three additional metabolites increased in urine of CKD dogs. They were methylguanidine (MG),
391 kynurenic acid (KnA) and dimethylamine (DA). These molecules are well known uremic toxins that
392 accumulate in serum and urine due to the impairment of renal function [74,75]. MG derives from
393 creatinine and is often detected in serum and urine of uremic human patients [76,77]. MG was
394 detected also in serum of uremic dogs and was shown to increase in urine of dogs affected by
395 transitional cell carcinoma [33,78]. In the present study, 14 samples were collected from dogs at
396 advanced CKD stages (serum creatinine > 2.1 mg/dL; IRIS 3 and 4). Therefore, the increase of MG
397 in urine of CKD dogs might be considered in further studies as a possible biomarker of advanced
398 CKD stages. KnA is a key inflammatory metabolite of the tryptophan catabolic pathway: the
399 degradation of tryptophan occurs through the formation of kynurenine, which in turn can be
400 transformed into KnA and other related metabolites. Kidneys are involved in tryptophan metabolism
401 either eliminating the catabolites or producing the enzymes involved in tryptophan metabolism. In
402 case of renal failure, these metabolites, which are physiologically excreted in urine, accumulate in
403 the blood, contributing to uremia. Accordingly, the study of [Rhee et al.](#), [79] reported that serum
404 levels of KnA increased with CKD development and severity. Moreover, increased KnA urinary
405 excretion was associated with adverse clinical outcomes in critically ill patients with acute kidney
406 injury [80] and four tryptophan metabolites, including urinary KnA, were reported to be associated
407 with an estimated glomerular filtration rate (eGFR) decline and with oxidative stress after eight years
408 follow-up [81,82].

409 Eight metabolites were significantly reduced in urine of CKD patients and the most consistent
410 decrease was evident for trigonelline, which can be obtained from the diet, or alternatively produced
411 as a niacin-derived metabolite. Proximal tubule epithelia synthesize NAD from precursors taken up
412 from urine and an excess of metabolites of the biosynthetic pathway, including trigonelline, is
413 normally secreted in urine. In case of tubular damage, a reduced/absent absorption of nicotinamide

414 or nicotinic acid occurs leading to a reduced/absent trigonelline secretion. Accordingly, in a mice
415 model of acute kidney injury, trigonelline removal from urine was reported as a consequence of
416 tubular damage [83–85].

417 Significant decrease was observed also for urocanic, indolelactic and trans-ferulic acids. The two first
418 metabolites derive from hepatic histidine and tryptophan catabolism, respectively. In particular,
419 histidine can be converted to histamine, 3-methylhistidine or urocanic acid by different pathways,
420 while indolelactic acid is obtained through the reduction of indolepyruvic acid derived by oxidative
421 deamination of tryptophan. Finally, trans-ferulic acid is a phenolic acid widely distributed in plants
422 that can be absorbed by the small intestine and excreted through the urine. All these metabolites can
423 be found in plasma and urine [22,31,86]. Serum indolelactic acid was recently associated to eGFR in
424 human CKD patients [87], but, to the best of our knowledge, no information is available in the
425 literature on the decrease of these metabolites in the urine of CKD patients. Further studies are
426 therefore needed to clarify their role as possible biomarkers.

427 This study presents some limitations. The first one is related to the different age between healthy and
428 diseased dogs. Since CKD is a disease of older animals, and adult/old dogs are usually presented to
429 the Veterinary Teaching Hospital due to pathologic conditions, it was not possible to collect samples
430 from age-matched controls. However, none of the different metabolites identified between healthy
431 and CKD dog were reported by Wang et al., [88] as affected by age in healthy dogs. Therefore, despite
432 a possible age effect on urine metabolome cannot be completely excluded, we hypothesise that the
433 effect of CKD was more consistent than the effect of the age. Secondly, the limited number of CKD
434 samples did not allow to highlight significant differences among CKD stages for both proteomics and
435 metabolomics results and it was not possible to highlight clear trends in biomarkers as the disease
436 worsen. The final limitation relates to the absence of technical replicates for the evaluation of the
437 robustness of our data. The technical evaluation of the performance of NMR applied to the dog urine
438 was out of the scope of the present research, especially since the high repeatability of NMR
439 metabolomics is well-known [20,21].

440

441 **Conclusions**

442 The integrated application of proteomics and metabolomics on urine samples yielded new insight into
443 the molecular complexity of urine in healthy dogs and highlighted biochemical changes in response
444 to CKD. SDS-PAGE evidenced the involvement of the tubular compartment with the decrease of
445 uromodulin and the presence of low MM bands also in non-proteinuric and non-azotaemic dogs and
446 could be considered a useful and complementary diagnostic tool for clinical pathologists, clinicians
447 and researchers working in veterinary nephrology and urology.

448 NMR metabolomics was successfully applied to canine urinary samples allowing the identification
449 of 86 metabolites. Of these, 17 showed significant differences in CKD dogs. In particular, the increase
450 of carnosine and cis-aconitic acid and the decrease of trigonelline are indicative of the tubular
451 involvement, adding further evidence to the results of SDS-PAGE. Additional studies are needed to
452 clarify the molecular mechanisms underlying the pathophysiology of CKD and to confirm the role of
453 the discovered metabolites as biomarkers of this disease in dogs. In particular, increasing the number
454 of urine samples collected from dogs affected by all stages of CKD should be the focus of future
455 research to confirm early biomarkers and highlight trends as the disease worsen.

456

457 **Funding**

458 EF was supported by a study grant from the Fondazione ItPA Onlus (2017, Rome, Italy). GI was
459 supported by a grant from University of Bologna (RFO). The NMR data were acquired at
460 CERMAX, ITQB-NOVA, Oeiras, Portugal with equipment funded by FCT, project AAC
461 01/SAICT/2016 and ONEIDA (LISBOA-01-0145-FEDER-016417) which is co-funded by FEEI -
462 "Fundos Europeus Estruturais e de Investimento" from "Programa Operacional Regional Lisboa
463 2020" and by national funds from FCT.

464

465 The funders had no role in study design, data collection and analysis, decision to publish, or
466 preparation of the manuscript

467

468

469 **References**

- 470 [1] D.J. Polzin, Chronic kidney disease in small animals, *Vet. Clin. North Am. Small Anim.*
471 *Pract.* 41 (2011) 15–30. doi:10.1016/j.cvsm.2010.09.004.
- 472 [2] D.G. O'Neill, J. Elliott, D.B. Church, P.D. McGreevy, P.C. Thomson, D.C. Brodbelt, Chronic
473 kidney disease in dogs in UK veterinary practices: Prevalence, risk factors, and survival, *J.*
474 *Vet. Intern. Med.* 27 (2013) 814–821. doi:10.1111/jvim.12090.
- 475 [3] J.W. Bartges, Chronic kidney disease in dogs and cats, *Vet. Clin. North Am. Small Anim.*
476 *Pract.* 42 (2012) 669–692. doi:10.1016/j.cvsm.2012.04.008.
- 477 [4] International Renal Interest Society, IRIS Staging of CKD (modified 2019), (2019) 1–8.
- 478 [5] S. Kovarikova, Indirect markers of glomerular filtration rate in dogs and cats: A review, *Vet.*
479 *Med. (Praha).* 63 (2018) 395–412. doi:10.17221/77/2017-VETMED.
- 480 [6] P. Pocar, P. Scarpa, A. Berrini, P. Cagnardi, R. Rizzi, V. Borromeo, Diagnostic potential of
481 simplified methods for measuring glomerular filtration rate to detect chronic kidney disease
482 in dogs, *J. Vet. Intern. Med.* 33 (2019) 2105–2116. doi:10.1111/jvim.15573.
- 483 [7] J.A. Hokamp, M.B. Nabity, Renal biomarkers in domestic species, *Vet. Clin. Pathol.* 45
484 (2016) 28–56. doi:10.1111/vcp.12333.
- 485 [8] E. Ferlizza, A. Campos, A. Neagu, A. Cuoghi, E. Bellei, E. Monari, F. Dondi, A.M.
486 Almeida, G. Isani, The effect of chronic kidney disease on the urine proteome in the
487 domestic cat (*Felis catus*), *Vet. J.* 204 (2015) 73–81. doi:10.1016/j.tvjl.2015.01.023.
- 488 [9] E. Ferlizza, F. Dondi, G. Andreani, D. Bucci, J. Archer, G. Isani, Validation of an
489 electrophoretic method to detect albuminuria in cats, *J. Feline Med. Surg.* 19 (2017) 860–
490 868. doi:10.1177/1098612X16664112.
- 491 [10] I. van Hoek, E. Meyer, L. Duchateau, K. Peremans, P. Smets, S. Daminet, Retinol-binding
492 protein in serum and urine of hyperthyroid cats before and after treatment with radioiodine, *J.*
493 *Vet. Intern. Med.* 23 (2009) 1031–1037. doi:10.1111/j.1939-1676.2009.0364.x.
- 494 [11] P.M.Y. Smets, E. Meyer, B.E.J. Maddens, L. Duchateau, S. Daminet, Urinary markers in

- 495 healthy young and aged dogs and dogs with chronic kidney disease, *J. Vet. Intern. Med.* 24
496 (2010) 65–72. doi:10.1111/j.1939-1676.2009.0426.x.
- 497 [12] M.B. Nabity, G.E. Lees, L.J. Dangott, R. Cianciolo, J.S. Suchodolski, J.M. Steiner,
498 Proteomic analysis of urine from male dogs during early stages of tubulointerstitial injury in
499 a canine model of progressive glomerular disease, *Vet. Clin. Pathol.* 40 (2011) 222–236.
500 doi:10.1111/j.1939-165X.2011.00307.x.
- 501 [13] T.L. Williams, J. Archer, Evaluation of urinary biomarkers for azotemic chronic kidney
502 disease in cats, *J. Small Anim. Pract.* 57 (2015) 122–129. doi:10.1111/jsap.12439.
- 503 [14] G. Isani, E. Ferlizza, J.E. Nally, Proteomic research in urine and other fluids, in: A.M. de
504 Almeida, P.D. Eckersall, I. Miller (Eds.), *Proteomics Domestic Animals: from Farm to*
505 *System Biology*, Springer, Cham, 2018: pp. 121–147. doi:10.1007/978-3-319-69682-9_7.
- 506 [15] I. Miller, A. Preßlmayer-Hartler, R. Wait, K. Hummel, C. Sensi, I. Eberini, E. Razzazi-
507 Fazeli, E. Gianazza, In between — Proteomics of dog biological fluids, *J. Proteomics.* 106
508 (2014) 30–45. doi:10.1016/j.jprot.2014.04.016.
- 509 [16] J. Kuleš, P. Bilić, B. Beer Ljubić, J. Gotić, M. Crnogaj, M. Brkljačić, V. Mrljak, Glomerular
510 and tubular kidney damage markers in canine babesiosis caused by *Babesia canis*, *Ticks*
511 *Tick. Borne. Dis.* 9 (2018) 1508–1517. doi:10.1016/j.ttbdis.2018.07.012.
- 512 [17] L. Pelander, V. Brunchault, B. Buffin-Meyer, J. Klein, B. Breuil, P. Zürgbig, P. Magalhães,
513 W. Mullen, J. Elliott, H. Syme, J.P. Schanstra, J. Häggström, I. Ljungvall, Urinary peptidome
514 analyses for the diagnosis of chronic kidney disease in dogs, *Vet. J.* 249 (2019) 73–79.
515 doi:10.1016/j.tvjl.2019.05.010.
- 516 [18] I.F. Duarte, S.O. Diaz, A.M. Gil, NMR metabolomics of human blood and urine in disease
517 research, *J. Pharm. Biomed. Anal.* 93 (2014) 17–26. doi:10.1016/j.jpba.2013.09.025.
- 518 [19] R.A. Silva, T.C.S. Pereira, A.R. Souza, P.R. Ribeiro, 1H NMR-based metabolite profiling for
519 biomarker identification, *Clin. Chim. Acta.* 502 (2020) 269–279.
520 doi:10.1016/j.cca.2019.11.015.

- 521 [20] J.L. Markley, R. Brüschweiler, A.S. Edison, H.R. Eghbalnia, R. Powers, D. Raftery, D.S.
522 Wishart, The future of NMR-based metabolomics, *Curr. Opin. Biotechnol.* 43 (2017) 34–40.
523 doi:10.1016/j.copbio.2016.08.001.
- 524 [21] P.G. Takis, V. Ghini, L. Tenori, P. Turano, C. Luchinat, 2019. Uniqueness of the NMR
525 approach to metabolomics, *Trends Anal. Chem.* 120, 115300.
526 doi:10.1016/j.trac.2018.10.036.
- 527 [22] S. Bouatra, F. Aziat, R. Mandal, A.C. Guo, M.R. Wilson, C. Knox, T.C. Bjorndahl, R.
528 Krishnamurthy, F. Saleem, P. Liu, Z.T. Dame, J. Poelzer, J. Huynh, F.S. Yallou, N.
529 Psychogios, E. Dong, R. Bogumil, C. Roehring, D.S. Wishart, 2013. The human urine
530 metabolome, *PLoS One.* 8, e73076. doi:10.1371/journal.pone.0073076.
- 531 [23] A. Julià, M. Vinaixa, E. Domènech, A. Fernández-Nebro, J.D. Cañete, C. Ferrándiz, J.
532 Tornero, J.P. Gisbert, P. Nos, A.G. Casbas, L. Puig, I. González-Álvaro, J.A. Pinto-Tasende,
533 R. Blanco, M.A. Rodríguez, A. Beltran, X. Correig, S. Marsal, E. Fernández, R. Sanmartí, J.
534 Gratacós, V.M. Martínez-Taboada, F. Gomollón, E. Daudén, J. Maymó, R. Queiró, F.J.L.
535 Longo, E. Garcia- Planella, J.L.S. Carazo, M. Alperi-López, C. Montilla, J.J. Pérez-Venegas,
536 B. Fernández-Gutiérrez, J.L. Mendoza, J.L. López Estebaranz, À. Olivé, J.C. Torre-Alonso,
537 M. Barreiro-de Acosta, D.M. Ramírez, H. Corominas, S. Muñoz-Fernández, J.L. Andreu, F.
538 Muñoz, P. de la Cueva, A. Erra, C.M. González, M.Á. Aguirre-Zamorano, M. Vera, F.
539 Vanaclocha, D. Roig, P. Vela, C. Saro, E. Herrera, P. Zarco, J.M. Nolla, M. Esteve, J.L.
540 Marenco de la Fuente, J.M. Pego-Reigosa, V. García-Sánchez, J. Panés, E. Fonseca, F.
541 Blanco, J. Rodríguez-Moreno, P. Carreira, J. Ramírez, G. ávila, L. Codó, J.L. Gelpí, A.C.
542 García-Montero, N. Palau, M. López-Lasanta, R. Tortosa, A. Alonso, 2016. Urine
543 metabolome profiling of immune-mediated inflammatory diseases, *BMC Med.* 14, 133.
544 doi:10.1186/s12916-016-0681-8.
- 545 [24] E.A. Mathé, A.D. Patterson, M. Haznadar, S.K. Manna, K.W. Krausz, E.D. Bowman, P.G.
546 Shields, J.R. Idle, P.B. Smith, K. Anami, D.G. Kazandjian, E. Hatzakis, F.J. Gonzalez, C.C.

- 547 Harris, Non-invasive urinary metabolomic profiling identifies diagnostic and prognostic
548 markers in lung cancer, *Cancer Res.* 74 (2014) 3259–3270. doi:10.1158/0008-5472.CAN-14-
549 0109.
- 550 [25] C.L. Silva, A. Olival, R. Perestrelo, P. Silva, H. Tomás, J.S. Câmara, 2019. Untargeted
551 urinary ¹H NMR-based metabolomic pattern as a potential platform in breast cancer
552 detection, *Metabolites*. 9, 269. doi:10.3390/metabo9110269.
- 553 [26] E.R. Kim, H.N. Kwon, H. Nam, J.J. Kim, S. Park, Y.H. Kim, 2019. Urine-NMR
554 metabolomics for screening of advanced colorectal adenoma and early stage colorectal
555 cancer, *Sci. Rep.* 9, 4786. doi:10.1038/s41598-019-41216-y.
- 556 [27] M. Martin-Lorenzo, L. Gonzalez-Calero, A. Ramos-Barron, M.D. Sanchez-Niño, C. Gomez-
557 Alamillo, J.M. García-Segura, A. Ortiz, M. Arias, F. Vivanco, G. Alvarez-Llamas, Urine
558 metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy
559 generation and H₂S availability, *J. Mol. Med.* 95 (2017) 1399–1409. doi:10.1007/s00109-
560 017-1594-5.
- 561 [28] M. Posada-Ayala, I. Zubiri, M. Martin-Lorenzo, A. Sanz-Maroto, D. Molero, L. Gonzalez-
562 Calero, B. Fernandez-Fernandez, F. De La Cuesta, C.M. Laborde, M.G. Barderas, A. Ortiz,
563 F. Vivanco, G. Alvarez-Llamas, Identification of a urine metabolomic signature in patients
564 with advanced-stage chronic kidney disease, *Kidney Int.* 85 (2014) 103–111.
565 doi:10.1038/ki.2013.328.
- 566 [29] M. Breit, K.M. Weinberger, Metabolic biomarkers for chronic kidney disease, *Arch.*
567 *Biochem. Biophys.* 589 (2016) 62–80. doi:10.1016/j.abb.2015.07.018.
- 568 [30] S. Hallan, M. Afkarian, L.R. Zelnick, B. Kestenbaum, S. Sharma, R. Saito, M. Darshi, G.
569 Barding, D. Raftery, W. Ju, M. Kretzler, K. Sharma, I.H. de Boer, Metabolomics and gene
570 expression analysis reveal down-regulation of the citric acid (TCA) Cycle in non-diabetic
571 CKD patients, *EBioMedicine*. 26 (2017) 68–77. doi:10.1016/j.ebiom.2017.10.027.
- 572 [31] S.-M. Rivera-Vélez, N.F. Villarino, Feline urine metabolomic signature: characterization of

low-molecular-weight substances in urine from domestic cats, *J. Feline Med. Surg.* 20 (2017) 155-163. doi:10.1177/1098612X17701010.

[32] J. Soder, R. Hagman, J. Dicksved, S. Lindase, K. Malmlof, P. Agback, A. Moazzami, K. Hoglund, S. Wernersson, 2017. The urine metabolome differs between lean and overweight Labrador Retriever dogs during a feed-challenge, *PLoS One*. 12, e0180086. doi:10.1371/journal.pone.0180086.

[33] J. Zhang, S. Wei, L. Liu, G.A. Nagana Gowda, P. Bonney, J. Stewart, D.W. Knapp, D. Raftery, NMR-based metabolomics study of canine bladder cancer, *Biochim. Biophys. Acta*. 1822 (2012) 1807–1814. doi:10.1016/j.bbadis.2012.08.001.

[34] Y.A. Lawrence, B.C. Guard, J.M. Steiner, J.S. Suchodolski, J.A. Lidbury, 2019. Untargeted metabolomic profiling of urine from healthy dogs and dogs with chronic hepatic disease, *PLoS One*. 14, e0217797. doi:10.1371/journal.pone.0217797.

[35] C. Zhu, V. Faillace, F. Laus, M. Bazzano, L. Laghi, 2018. Characterization of trotter horses urine metabolome by means of proton nuclear magnetic resonance spectroscopy, *Metabolomics*. 14, 106. doi:10.1007/s11306-018-1403-3.

[36] G. Isani, E. Ferlizza, A. Cuoghi, E. Bellei, E. Monari, B. Bianchin Butina, C. Castagnetti, Identification of the most abundant proteins in equine amniotic fluid by a proteomic approach, *Anim. Reprod. Sci.* 174 (2016) 150–160. doi:10.1016/j.anireprosci.2016.10.003.

[37] D. Jacob, C. Deborde, M. Lefebvre, M. Maucourt, A. Moing, 2017. NMRProcFlow: a graphical and interactive tool dedicated to 1D spectra processing for NMR-based metabolomics, *Metabolomics*. 13, 36. doi:10.1007/s11306-017-1178-y.

[38] J. Xia, D.S. Wishart, 2016. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis, *Curr. Protoc. Bioinforma.* 55. doi:10.1002/cpbi.11.

[39] M. Palma, L.E. Hernández-Castellano, N. Castro, A. Arguëllo, J. Capote, M. Matzapetakis, A.M. de Almeida, NMR-metabolomics profiling of mammary gland secretory tissue and milk serum in two goat breeds with different levels of tolerance to seasonal weight loss, *Mol.*

599 BioSyst. 12 (2016) 2094–2107. doi:10.1039/C5MB00851D.

- 600 [40] E. Szymańska, E. Saccenti, A.K. Smilde, J.A. Westerhuis, Double-check: Validation of
601 diagnostic statistics for PLS-DA models in metabolomics studies, *Metabolomics*. 8 (2012) 3–
602 16. doi:10.1007/s11306-011-0330-3.
- 603 [41] J.A. Hokamp, R.E. Cianciolo, M. Boggess, G.E. Lees, S.L. Benali, M. Kovarsky, M.B.
604 Nabity, Correlation of urine and serum biomarkers with renal damage and survival in dogs
605 with naturally occurring proteinuric chronic kidney disease, *J. Vet. Intern. Med.* 30 (2016)
606 591–601. doi:10.1111/jvim.13832.
- 607 [42] J.A. Hokamp, S.A. Leidy, I. Gaynanova, R.E. Cianciolo, M.B. Nabity, Correlation of
608 electrophoretic urine protein banding patterns with severity of renal damage in dogs with
609 proteinuric chronic kidney disease, *Vet. Clin. Pathol.* 47 (2018) 425–434.
610 doi:10.1111/vcp.12648.
- 611 [43] F. Chacar, M. Kogika, T.R. Sanches, D. Caragelasco, C. Martorelli, C. Rodrigues, J.M.C.
612 Capcha, D. Chew, L. Andrade, 2017. Urinary Tamm-Horsfall protein, albumin, vitamin D-
613 binding protein, and retinol-binding protein as early biomarkers of chronic kidney disease in
614 dogs, *Physiol. Rep.* 5, e13262. doi:10.14814/phy2.13262.
- 615 [44] R. Cianciolo, J. Hokamp, M. Nabity, Advances in the evaluation of canine renal disease, *Vet.*
616 *J.* 215 (2016) 21–29. doi:10.1016/j.tvjl.2016.04.012.
- 617 [45] O. Jaturakan, M. Vanichwatanaramlouk, A. Kornkaew, M. Trisiriroy, SDS-PAGE
618 electrophoresis for urinary protein analysis in dogs with chronic kidney disease and urinary
619 tract infection, *Thai J. Vet. Med.* 43 (2013) 75–83.
- 620 [46] D.S. Caragelasco, M.M. Kogika, C.R. Martorelli, K.K. Kanayama, D.M.N. Simões, Urine
621 protein electrophoresis study in dogs with pituitary dependent hyperadrenocorticism during
622 therapy with trilostane, *Pesqui. Vet. Bras.* 37 (2017) 734–740. doi:10.1590/s0100-
623 736x2017000700014.
- 624 [47] G. Segev, M.B. Nabity, G.F. Grauer, S. Brown, D.J. Polzin, L.D. Cowgill, C. Langston,

- 625 A.M. van Dongen, J. Elliott, Is progressive chronic kidney disease a slow acute kidney
626 injury?, *Vet. Clin. North Am. Small Anim. Pract.* 46 (2016) 995–1013.
627 doi:10.1016/j.cvsm.2016.06.001.
- 628 [48] J. Raila, H. Aupperle, G. Raila, Renal pathology and urinary protein excretion in a 14-month-
629 old Bernese mountain dog with chronic renal failure, *J. Vet. Med A.* 54 (2007) 131–135.
630 doi:10.1111/j.1439-0442.2007.00919.x.
- 631 [49] J. Raila, L. Brunnberg, Influence of kidney function on urinary excretion of albumin and
632 retinol-binding protein in dogs with naturally occurring renal disease, *Am. J. Vet. Res.* 71
633 (2010) 1387–1394. doi:10.2460/ajvr.71.11.1387.
- 634 [50] J. Raila, F.J. Schweigert, B. Kohn, Relationship between urinary Tamm-Horsfall protein
635 excretion and renal function in dogs with naturally occurring renal disease, *Vet. Clin. Pathol.*
636 43 (2014) 261–265. doi:10.1111/vcp.12143.
- 637 [51] O. Devuyst, E. Olinger, L. Rampoldi, Uromodulin: from physiology to rare and complex
638 kidney disorders., *Nat. Rev. Nephrol.* 13 (2017) 525–544. doi:10.1038/nrneph.2017.101.
- 639 [52] A. Okubo, A. Nakashima, S. Doi, T. Doi, T. Ueno, K. Maeda, R. Tamura, K. Yamane, T.
640 Masaki, High-normal albuminuria is strongly associated with incident chronic kidney disease
641 in a nondiabetic population with normal range of albuminuria and normal kidney function,
642 *Clin. Exp. Nephrol.* (2020). doi:10.1007/s10157-019-01842-2.
- 643 [53] J. Martinez, C. Kellogg, M.C. Iazbik, C.G. Couto, B.M. Pressler, T.M. Hoepf, M.J. Radin,
644 The renin-angiotensin-aldosterone system in Greyhounds and non-Greyhound dogs, *J. Vet.*
645 *Intern. Med.* 31 (2017) 988–993. doi:10.1111/jvim.14720.
- 646 [54] A. Bacic, M.M. Kogika, K.C. Barbaro, C.S. Iuamoto, D.M.N. Simões, M.L. Santoro,
647 Evaluation of albuminuria and its relationship with blood pressure in dogs with chronic
648 kidney disease., *Vet. Clin. Pathol.* 39 (2010) 203–209. doi:10.1111/j.1939-
649 165X.2009.00207.x.
- 650 [55] C.Z. Cavalcante, M.M. Kogika, A. Bacic, M.L. Santoro, S.I. Miyashiro, J.P. Sault, M.K.

651 Oyafuso, D.M. Simões, Evaluation of albuminuria and electrophoresis of urinary proteins
652 from dogs with hyperadrenocorticism and relation with systemic arterial pressure, *Pesqui.*
653 *Vet. Bras.* 33 (2013) 1354–1363. doi:10.1590/S0100-736X2013001100013.

654 [56] P.M.Y. Smets, H.P. Lefebvre, B.P. Meij, S. Croubels, E. Meyer, I. Van de Maele, S.
655 Daminet, Long-term follow-up of renal function in dogs after treatment for ACTH-dependent
656 hyperadrenocorticism., *J. Vet. Intern. Med.* 26 (2012) 565–574. doi:10.1111/j.1939-
657 1676.2012.00915.x.

658 [57] O.L. Ioannis, S. Nectarios, C. Jose Joaquin, T. Konstantina, R. Timoleon, P. Zoe, The
659 prognostic value of microalbuminuria in puppies with canine parvoviral enteritis, *Acta Vet.*
660 *Brno.* 69 (2019) 116–122. doi:10.2478/acve-2019-0008.

661 [58] H. Schaefer, B. Kohn, F.J. Schweigert, J. Raila, Quantitative and qualitative urine protein
662 excretion in dogs with severe inflammatory response syndrome., *J. Vet. Intern. Med.* 25
663 (2011) 1292–1297. doi:10.1111/j.1939-1676.2011.00829.x.

664 [59] S.L. Vaden, C.A. Turman, T.L. Harris, S.L. Marks, The prevalence of albuminuria in dogs
665 and cats in an ICU or recovering from anesthesia., *J. Vet. Emerg. Crit. Care.* 20 (2010) 479–
666 487. doi:10.1111/j.1476-4431.2010.00584.x.

667 [60] Y.H. Lien, T.Y. Hsiang, H.P. Huang, Associations among systemic blood pressure,
668 microalbuminuria and albuminuria in dogs affected with pituitary- and adrenal-dependent
669 hyperadrenocorticism., *Acta Vet. Scand.* 52 (2010) 61. doi:10.1186/1751-0147-52-61.

670 [61] J. Whittemore, B. Marcum, D. Mawby, M. Coleman, T. Hacket, L. Lappin, Associations
671 among albuminuria, C-reactive protein concentrations, survival predictor index scores, and
672 survival in 78 critically ill dogs, *J. Vet. Intern. Med.* 25 (2011) 818–824.

673 [62] R. Troia, M. Gruarin, C. Grisetti, F. Serafini, L. Magna, E. Monari, M. Giunti, F. Dondi,
674 Fractional excretion of electrolytes in volume-responsive and intrinsic acute kidney injury in
675 dogs: Diagnostic and prognostic implications, *J. Vet. Intern. Med.* 32 (2018) 1372–1382.
676 doi:10.1111/jvim.15146.

- 677 [63] M.R. Viant, C. Ludwig, S. Rhodes, U.L. Günther, D. Allaway, Validation of a urine
678 metabolome fingerprint in dog for phenotypic classification, *Metabolomics*. 3 (2007) 453–
679 463. doi:10.1007/s11306-007-0092-0.
- 680 [64] G. Carlos, F.P. dos Santos, P.E. Fröhlich, 2020. Canine metabolomics advances,
681 *Metabolomics*. 16, 16. doi:10.1007/s11306-020-1638-7.
- 682 [65] G.M. Forster, J. Stockman, N. Noyes, A.L. Heuberger, C.D. Broeckling, C.M. Bantle, E.P.
683 Ryan, A comparative study of serum biochemistry, metabolome and microbiome parameters
684 of clinically healthy, normal weight, overweight, and obese companion dogs, *Top.*
685 *Companion Anim. Med.* 33 (2018) 126–135. doi:10.1053/j.tcam.2018.08.003.
- 686 [66] D. Jappar, Y. Hu, R.F. Keep, D.E. Smith, Transport mechanisms of carnosine in SKPT cells:
687 Contribution of apical and basolateral membrane transporters, *Pharm. Res.* 26 (2009) 172–
688 181. doi:10.1007/s11095-008-9726-9.
- 689 [67] V. Peters, C.Q.F. Klessens, H.J. Baelde, B. Singler, K.A.M. Veraar, A. Zutinic, J. Drozak, J.
690 Zschocke, C.P. Schmitt, E. De Heer, Intrinsic carnosine metabolism in the human kidney,
691 *Amino Acids*. 47 (2015) 2541–2550. doi:10.1007/s00726-015-2045-7.
- 692 [68] K. Kilis-Pstrusinska, 2020. Carnosine and kidney diseases: what we currently know?, *Curr.*
693 *Med. Chem.* 20. doi:10.2174/0929867326666190730130024.
- 694 [69] M. Urpi-Sarda, E. Almanza-Aguilera, R. Llorach, R. Vázquez-Fresno, R. Estruch, D.
695 Corella, J. V. Sorli, F. Carmona, A. Sanchez-Pla, J. Salas-Salvadó, C. Andres-Lacueva, Non-
696 targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional
697 study of PREDIMED trial participants, *Diabetes Metab.* 45 (2019) 167–174.
698 doi:10.1016/j.diabet.2018.02.006.
- 699 [70] C.J. Chen, W.L. Liao, C.T. Chang, Y.N. Lin, F.J. Tsai, Identification of urinary metabolite
700 biomarkers of type 2 diabetes nephropathy using an untargeted metabolomic approach, *J.*
701 *Proteome Res.* 17 (2018) 3997–4007. doi:10.1021/acs.jproteome.8b00644.
- 702 [71] D.Q. Chen, G. Cao, H. Chen, D. Liu, W. Su, X.Y. Yu, N.D. Vaziri, X.H. Liu, X. Bai, L.

703 Zhang, Y.Y. Zhao, Gene and protein expressions and metabolomics exhibit activated redox
 704 signaling and wnt/ β -catenin pathway are associated with metabolite dysfunction in patients
 705 with chronic kidney disease, *Redox Biol.* 12 (2017) 505–521.
 706 doi:10.1016/j.redox.2017.03.017.

707 [72] R.E. Silva, J.L. Baldim, D.A. Chagas-Paula, M.G. Soares, J.H.G. Lago, R. V. Gonçalves,
 708 R.D. Novaes, Predictive metabolomic signatures of end-stage renal disease: A multivariate
 709 analysis of population-based data, *Biochimie.* 152 (2018) 14–30.
 710 doi:10.1016/j.biochi.2018.06.009.

711 [73] C.M. Rivara, C.R. Johnson, J.P. Lulich, C.A. Osborne, M. Murtaugh, 2013. The effect of
 712 disease on the urinary purine metabolite concentrations in dogs, *Vet. Rec.* 173, 219.
 713 doi:10.1136/vr.101237.

714 [74] F. Duranton, G. Cohen, R. De Smet, M. Rodriguez, J. Jankowski, R. Vanholder, A. Argiles,
 715 Normal and pathologic concentrations of uremic toxins, *J. Am. Soc. Nephrol.* 23 (2012)
 716 1258–1270. doi:10.1681/ASN.2011121175.

717 [75] M.A. Risso, S. Sallustio, V. Sueiro, V. Bertoni, H. Gonzalez-Torres, C.G. Musso, The
 718 importance of tubular function in chronic kidney disease, *Int. J. Nephrol. Renovasc. Dis.* 12
 719 (2019) 257–262. doi:10.2147/IJNRD.S216673.

720 [76] K. Ienaga, K. Nakamura, T. Fujisawa, Y. Fukunaga, H. Nihei, M. Narita, Y. Tomino, T.
 721 Sanaka, K. Aoyagi, K. Nakano, H. Koide, Urinary excretion of creatol, an in vivo biomarker
 722 of hydroxyl radical, in patients with chronic renal failure, *Ren. Fail.* 29 (2007) 279–283.
 723 doi:10.1080/08860220701219863.

724 [77] N. Neirynck, R. Vanholder, E. Schepers, S. Eloot, A. Pletinck, G. Glorieux, An update on
 725 uremic toxins, *Int. Urol. Nephrol.* 45 (2013) 139–150. doi:10.1007/s11255-012-0258-1.

726 [78] A.M. Bosco, B.F.M. Almeida, P.P. Pereira, D.B. dos Santos, J.S. Neto, W.L. Ferreira, P.C.
 727 Ciarlini, The uremic toxin methylguanidine increases the oxidative metabolism and
 728 accelerates the apoptosis of canine neutrophils, *Vet. Immunol. Immunopathol.* 185 (2017)

729 14–19. doi:10.1016/j.vetimm.2017.01.006.

730 [79] E.P. Rhee, C.B. Clish, A. Ghorbani, M.G. Larson, S. Elmariah, E. McCabe, Q. Yang, S.
731 Cheng, K. Pierce, A. Deik, A.L. Souza, L. Farrell, C. Domos, R.W. Yeh, I. Palacios, K.
732 Rosenfield, R.S. Vasan, J.C. Florez, T.J. Wang, C.S. Fox, R.E. Gerszten, A combined
733 epidemiologic and metabolomic approach improves CKD prediction, *J. Am. Soc. Nephrol.*
734 24 (2013) 1330–1338. doi:10.1681/ASN.2012101006.

735 [80] F. Aregger, D.E. Uehlinger, G. Fusch, A. Bahonjic, R. Pschowski, M. Walter, J.C. Schefold,
736 2018. Increased urinary excretion of kynurenic acid is associated with non-recovery from
737 acute kidney injury in critically ill patients, *BMC Nephrol.* 19, 44. doi:10.1186/s12882-018-
738 0841-5.

739 [81] C. Barrios, T.D. Spector, C. Menni, Blood, urine and faecal metabolite profiles in the study
740 of adult renal disease, *Arch. Biochem. Biophys.* 589 (2016) 81–92.
741 doi:10.1016/j.abb.2015.10.006.

742 [82] A.L. Saucedo, M.M. Perales-Quintana, D. Paniagua-Vega, C. Sanchez-Martinez, P. Cordero-
743 Perez, N.W. Minsky, Chronic Kidney Disease and the Search for New Biomarkers for Early
744 Diagnosis, *Curr. Med. Chem.* 25 (2018) 3719–3747.
745 doi:10.2174/0929867325666180307110908.

746 [83] T. Chihanga, Q. Ma, J.D. Nicholson, H.N. Ruby, R.E. Edelmann, P. Devarajan, M.A.
747 Kennedy, NMR spectroscopy and electron microscopy identification of metabolic and
748 ultrastructural changes to the kidney following ischemia-reperfusion injury, *Am. J. Physiol.*
749 *Physiol.* 314 (2018) 154–166. doi:10.1152/ajprenal.00363.2017.

750 [84] M.A. Hanifa, M. Skott, R.G. Maltesen, B.S. Rasmussen, S. Nielsen, J. Frøkiær, T. Ring, R.
751 Wimmer, 2019. Tissue, urine and blood metabolite signatures of chronic kidney disease in
752 the 5/6 nephrectomy rat model, *Metabolomics.* 15, 112. doi:10.1007/s11306-019-1569-3.

753 [85] A.J. Won, S. Kim, Y.G. Kim, K.B. Kim, W.S. Choi, S. Kacew, K.S. Kim, J.H. Jung, B.M.
754 Lee, S. Kim, H.S. Kim, Discovery of urinary metabolomic biomarkers for early detection of

755 acute kidney injury, *Mol. Biosyst.* 12 (2016) 133–144. doi:10.1039/c5mb00492f.

756 [86] Y. He, W. Su, T. Chen, X. Zeng, Z. Yan, J. Guo, W. Yang, H. Wu, 2019. Identification of
757 prototype compounds and derived metabolites of naoxintong capsule in beagle dog urine and
758 feces by UFLC-Q-TOF-MS/MS, *J. Pharm. Biomed. Anal.* 176, 112806.
759 doi:10.1016/j.jpba.2019.112806.

760 [87] S.M. Titan, G. Venturini, K. Padilha, G. Tavares, R. Zatz, I. Bensenor, P.A. Lotufo, E.P.
761 Rhee, R.I. Thadhani, A.C. Pereira, Metabolites related to eGFR: Evaluation of candidate
762 molecules for GFR estimation using untargeted metabolomics, *Clin. Chim. Acta.* 489 (2019)
763 242–248. doi:10.1016/j.cca.2018.08.037.

764 [88] Y. Wang, D. Lawler, B. Larson, Z. Ramadan, S. Kochhar, E. Holmes, J.K. Nicholson,
765 Metabonomic investigations of aging and caloric restriction in a life-long dog study, *J.*
766 *Proteome Res.* 6 (2007) 1846–1854. doi:10.1021/pr060685n.

767

768 Table 1. Clinical data for healthy and CKD dogs. Data are reported as mean \pm SD or median (range)
 769 depending on normal or non-normal distribution, respectively.

Signalment	Healthy (N=22)	CKD (N=28)	<i>P</i>		
Age in months	37 \pm 20	112 \pm 61	<0.0001		
Female n (entire/neutered)	12 (5/7)	14 (5/9)			
Male n (entire/neutered)	10 (7/3)	14 (9/5)			
Serum biochemistry	Healthy	CKD	N (%) CKD < / > RI	RI	
Total Proteins (g/dL)	6.4 \pm 0.4	6.0 \pm 0.8	5 (17.9) < / 1 (3.6) >	5.6-7.3	0.109
Albumin (g/dL)	3.4 \pm 0.3	3.0 (1.1-3.8)	12 (42.9) <	2.8-3.9	<0.0001
Creatinine (mg/dL)	1.1 \pm 0.2	2.0 (0.6-9.8)	1 (3.6) < / 20 (71.4) >	0.8-1.4	<0.0001
Urea (mg/dL)	33 \pm 8	110 (17-519)	22 (78.6) >	17-48	<0.0001
Phosphorus (mg/dL)	4.6 \pm 0.9	4.9 (2.6-14.1)	11 (39.3) >	2.7-5.4	0.056
Urine biochemistry	Healthy	CKD	N (%) CKD < / > RI	RI	
UPC	0.07 (0.04-0.19)	0.78 (0.09-12.8)	18 (64.3) >	< 0.5	<0.0001
USG	1052 (1034-1064)	1014 (1006-1062)	27 (96.4) <	> 1.030 ^a	<0.0001
IRIS Stage	N (%)		RI		
I	8 (28.6)		< 1.4		
II	6 (21.4)		1.4-2.0		
III	9 (32.1)		2.1-5.0		
IV	5 (17.8)		> 5.0		

770

771 RI, reference intervals; N, number of samples; UPC, urine protein to creatinine ratio; USG, urine
 772 specific gravity;

773 ^a Considered as adequate USG in dogs.

774

775 Table 2. Proteins identified in dog urine by mass spectrometry.

Protein name	Protein entry name ^a	MM (kDa) ^b	Score ^c	Pept ^d	Sign Pept ^e	Seq ^f	Sign seq ^g
Uromodulin	UROM_CANFA	73	2298	138	113	15	13
Albumin	ALBU_CANFA	69	5802	470	321	44	39
Arginine esterase	ESTA_CANFA	29	532	111	52	10	9

776

777 ^a Protein entry name from UniProt knowledge database.

778 ^b Theoretical protein molecular mass.

779 ^c The highest scores obtained with Mascot search engine.

780 ^d Peptides: total number of peptides matching the identified proteins.

781 ^e Significant peptides: total number of significant peptides matching the identified proteins.

782 ^f Sequence: total number of distinct sequences matching the identified proteins.

783 ^g Significant sequences: total number of significant distinct sequences matching the identified
784 proteins.

785 Table 3. Data for albumin and uromodulin quantification by SDS-PAGE. Data are reported as
786 mean±SD or median (range) depending on normal or non-normal distribution, respectively.

787

	HEALTHY	CKD	<i>P</i>
Albumin (mg/dl)	3.1±1.4	26.6 (1.4-228.9)	0.0025
UAC	0.010±0.007	0.213 (0.028-1.395)	0.0002
Uromodulin (mg/dl)	11.9±2.3	0 (0-5.1)	<0.0001
UMC	0.038±0.012	0 (0-0.044)	0.0044

788

789

790 Table 4. Assigned metabolites in the urine of healthy dog. Biological function, process and pathway
 791 are also indicated.

Query	HMDB	PubChem	KEGG
1,7-Dimethylxanthine	HMDB0001860	4687	C13747
1-Methyladenosine	HMDB0003331	27476	C02494
1-Methylguanine	HMDB0003282	70315	C04152
1-Methylhistidine	HMDB0000001	92105	C01152
1-Methylnicotinamide	HMDB0000699	457	C02918
2-Furoylglycine	HMDB0000439	21863	NA
2-Hydroxybutyric acid	HMDB0000008	11266	C05984
2-Hydroxyphenylacetic acid	HMDB0000669	11970	C05852
2-Ketobutyric acid	HMDB0000005	58	C00109
2-Methylglutaric acid	HMDB0000422	12046	NA
3-Aminoisobutyric acid	HMDB0003911	64956	C05145
3-Hydroxyphenylacetic acid	HMDB0000440	12122	C05593
3-Indoxylsulfic acid	HMDB0000682	10258	NA
3-Methyl-2-oxovaleric acid	HMDB0000491	47	C03465
3-Methylglutaric acid	HMDB0000752	12284	NA
3-Methylxanthine	HMDB0001886	70639	C16357
4-Aminohippuric acid	HMDB0001867	2148	NA
4-Hydroxybenzoic acid	HMDB0000500	135	C00156
4-Hydroxyphenylacetic acid	HMDB0000020	127	C00642
4-Pyridoxic acid	HMDB0000017	6723	C00847
7-Methyladenine	HMDB0011614	71593	C02241
7-Methylxanthine	HMDB0001991	68374	C16353
Acetic acid	HMDB0000042	176	C00033
Acetylcysteine	HMDB0001890	12035	C06809
Adenosine	HMDB0000050	60961	C00212
Alanine	HMDB0000161	5950	C00041
Allantoin	HMDB0000462	204	C01551
Arabinitol	HMDB0001851	439255	C00532
Ascorbic acid	HMDB0000044	54670067	C00072
Betaine	HMDB0000043	247	C00719
Carnitine	HMDB0000062	2724480	C00318
Choline	HMDB0000097	305	C00114
cis-Aconitic acid	HMDB0000072	643757	C00417
Citric acid	HMDB0000094	311	C00158
Creatine	HMDB0000064	586	C00300
Creatine phosphate	HMDB0001511	587	C02305
Creatinine	HMDB0000562	588	C00791
Cytosine	HMDB0000630	597	C00380
Dimethylamine	HMDB0000087	674	C00543
Ferulic acid	HMDB0000954	445858	C01494
Formic acid	HMDB0000142	284	C00058

Fucose	HMDB0000174	17106	C01019
Galactonic acid	HMDB0000565	128869	C00880
Galactose	HMDB0000143	439357	C00984
Glucaric acid	HMDB0000663	33037	C00818
Glucuronic acid	HMDB0000127	444791	C00191
Glycine	HMDB0000123	750	C00037
Glycolic acid	HMDB0000115	757	C00160
Glyoxylic acid	HMDB0000119	760	C00048
Hippuric acid	HMDB0000714	464	C01586
Histidine	HMDB0000177	6274	C00135
Hypoxanthine	HMDB0000157	790	C00262
3-Methylhistidine	HMDB0000479	64969	C01152
Indole-3-lactic acid	HMDB0000671	92904	C02043
Isobutyric acid	HMDB0001873	6590	C02632
Isoleucine	HMDB0000172	6306	C00407
Kynurenic acid	HMDB0000715	3845	C01717
Lactic acid	HMDB0000190	107689	C00186
Lysine	HMDB0000182	5962	C00047
Mannitol	HMDB0000765	6251	C00392
Methylguanidine	HMDB0001522	10111	C02294
N,N-Dimethylglycine	HMDB0000092	673	C01026
N6-Acetyllysine	HMDB0000206	92832	C02727
N-Acetylglycine	HMDB0000532	10972	NA
N-Phenylacetylglycine	HMDB0000821	68144	C05598
Oxoglutaric acid	HMDB0000208	51	C00026
Phosphorylcholine	HMDB0001565	1014	C00588
Pseudouridine	HMDB0000767	15047	C02067
Pyridoxamine	HMDB0001431	1052	C00534
Serine	HMDB0000187	5951	C00065
Succinic acid	HMDB0000254	1110	C00042
Taurine	HMDB0000251	1123	C00245
Threonine	HMDB0000167	6288	C00188
trans-Aconitic acid	HMDB0000958	444212	C02341
Trigonelline	HMDB0000875	5570	C01004
Trimethylamine	HMDB0000906	1146	C00565
Trimethylamine N-oxide	HMDB0000925	1145	C01104
Tryptophan	HMDB0000929	6305	C00078
Tyramine	HMDB0000306	5610	C00483
Tyrosine	HMDB0000158	6057	C00082
Uracil	HMDB0000300	1174	C00106
Urea	HMDB0000294	1176	C00086
Urocanic acid	HMDB0000301	736715	C00785
Valine	HMDB0000883	6287	C00183
Xanthine	HMDB0000292	1188	C00385
Xanthosine	HMDB0000299	64959	C01762
Xanthurenic acid	HMDB0000881	5699	C02470

792 Table 5. Significant pathways obtained by the pathway analysis module of MetaboAnalyst.

Pathway	Total ^a	Hits ^b	Raw p	Metabolites
Glycine, serine and threonine metabolism	48	10	1.94E-06	L-Serine; Choline; Betaine; Dimethylglycine; Glycine; L-Threonine; Creatine; 2-Ketobutyric acid; Glyoxylic acid; L-Tryptophan
Phenylalanine metabolism	45	8	7.59E-05	Hippuric acid; Phenylacetylglutamine; Succinic acid; Ortho-Hydroxyphenylacetic acid; 4-Hydroxybenzoic acid; p-Hydroxyphenylacetic acid; L-Tyrosine; 3-Hydroxyphenylacetic acid
Aminoacyl-tRNA biosynthesis	75	10	0.00012	L-Histidine; Glycine; L-Serine; L-Valine; L-Alanine; L-Lysine; L-Isoleucine; L-Threonine; L-Tryptophan; L-Tyrosine
Caffeine metabolism	21	6	0.000452	Paraxanthine; 3-Methylxanthine; 7-Methylxanthine; Xanthosine; Xanthine; Glyoxylic acid
Methane metabolism	34	6	0.000666	Glycine; Formic acid; Trimethylamine; Trimethylamine N-oxide; Dimethylamine; L-Serine;
Glyoxylate and dicarboxylate metabolism	50	7	0.001004	cis-Aconitic acid; Glyoxylic acid; Oxoglutaric acid; Formic acid; Glycolic acid; Citric acid; Succinic acid;
Nitrogen metabolism	39	6	0.001418	L-Tyrosine; L-Tryptophan; Taurine; L-Histidine; Glycine; Formic acid;
Citrate cycle (TCA cycle)	20	4	0.00349	Succinic acid; Oxoglutaric acid; cis-Aconitic acid; Citric acid;
Propanoate metabolism	35	5	0.005027	2-Ketobutyric acid; Succinic acid; L-Lactic acid; 2-Hydroxybutyric acid; L-Valine;
Valine, leucine and isoleucine biosynthesis	27	4	0.010619	L-Threonine; L-Valine; L-Isoleucine; 2-Ketobutyric acid;
Taurine and hypotaurine metabolism	20	3	0.025942	Taurine; L-Alanine; Acetic acid;
Purine metabolism	92	8	0.029144	Xanthine; Adenosine; Xanthosine; Hypoxanthine; Urea; Glyoxylic acid; Glycine; Allantoin
Alanine, aspartate and glutamate metabolism	24	3	0.041947	L-Alanine; Oxoglutaric acid; Succinic acid;
Pyrimidine metabolism	60	5	0.044772	Cytosine; Uracil; Pseudouridine; Urea; 3-Aminoisobutanoic acid;

793
794 ^a Total metabolites belonging to the pathway as reported by the pathway analysis module of
795 MetaboAnalyst.

796 ^b Metabolites assigned in urine of healthy dogs belonging to the pathway as obtained by the
797 pathway analysis module of MetaboAnalyst.

798

799

800 Table 6. Metabolites showing significant differences

Bucket	Metabolite	Fold change CKD/Healthy	VIP score ^a	<i>P</i> value
B6_9876	Carnosine	3.15	1.922	0.001
B3_9190	7-Methylxanthine	2.94	1.444	0.037
B5_6610	cis-Aconitic acid	2.67	1.754	0.014
B2_7085	Dimethylamine	1.86	1.512	0.017
B2_8135	Methylguanidine	1.80	1.415	0.025
B7_8490	Kynurenic acid	1.77	1.333	0.045
B5_8415	Xanthosine	1.72	2.054	0.002
B4_2825	Pseudouridine	1.70	1.886	0.002
B7_6681	Pseudouridine	1.59	2.294	0.000
B5_3745	Allantoin	1.47	2.051	0.007
B7_3740	Urocanic acid	0.49	1.323	0.032
B0_9355	2-Hydroxybutyrric acid	0.48	1.343	0.005
B1_0360	L-Valine	0.44	1.583	0.010
B7_7874	4-Hydroxybenzoic acid	0.40	1.278	0.042
B7_1303	trans-Ferulic acid	0.34	1.566	0.009
B8_1155	7-Methyladenine	0.32	1.360	0.030
B7_7217	Indolelactic acid	0.26	1.450	0.018
B6_3648	trans-Ferulic acid	0.26	1.590	0.009
B6_3739	Urocanic acid	0.21	1.713	0.005
B8_8262	Trigonelline	0.15	1.284	0.043
B9_1121	Trigonelline	0.10	1.345	0.034

^a Variable Importance in Projection (VIP) scores

804 Fig. 1. Representative SDS-PAGE gels of urine samples from healthy and CKD dogs. Black
805 continuous box indicates uromodulin (103 kDa); black dotted box indicates albumin (67 kDa);
806 black dashed box indicates the internal standard of quantity (1 μ g); black dashed and dotted box
807 indicates arginine esterase (18 kDa). M, male; MC, male castrated; F, female; FS, female spayed.
808 LMM, low molecular mass (kDa<67kDa); HMM high molecular mass (kDa>67kDa). S1-4 under
809 each lane indicate the CKD stage of the patient according to IRIS guideline. NP (non-proteinuric,
810 UPC < 0.2), BP (borderline proteinuric, UPC 0.2 - 0.5) or P (proteinuric, UPC>0.5) under each lane
811 indicate the classification of proteinuria according to IRIS guideline.

812 Fig. 2. Representative NMR spectra of urine samples collected from healthy and CKD dogs.

813 Fig. 3. Representative spectrum of urine from CKD and healthy dog. For a better visualisation, the
814 spectrum has been divided into four parts. a) From 0.0 to 2.8 ppm; b) from 2.4 to 4.9 ppm; c) from
815 4.6 to 7.0 ppm; d) from 7.0 to 10.0 ppm. The reported metabolites are: 1 valine; 2 fucose; 3 lactate; 4
816 alanine; 5 acetate; 6 N6-acetyllysine; 7 N-acetylglycine; 8 acetylcysteine; 9 succinate; 10
817 pyridoxamine; 11 citrate; 12 dimethylamine; 13 methylguanidine; 14 trimethylamine; 15 N,N-
818 dimethylglycine; 16 creatine; 17 creatinine; 18 choline; 19 phosphorylcholine; 20 carnitine; 21
819 taurine, trimethylamine N-oxyde, betaine; 22 Taurine; 23 trans-aconitate; 24 3-hydroxyphenilacetate;
820 25 3-methylxantine; 26 2-hydroxyphenilacetate; 27 glycine; 28 N-phenylacetylglucine; 29 7-
821 methylxantine; 30 creatine, creatine phosphate, glycolate; 31 pseudouridine; 32 trigonelline; 33 1-
822 methylnicotinamide; 34 allantoin; 35 cis-aconitate; 36 urea; 37 xanthosine; 38 cytosine; 39
823 urocanate; 40 tyramine, tyrosine; 41 1-methylhistidine; 42 histidine; 43 3-indoxylsulphate; 44
824 tyramine; 45 hippurate; 46 hypoxanthine.

825 Fig. 4. a) Principal component analysis (PCA) score plot of healthy (crosses and dark grey circle)
826 and CKD (triangles and faint grey circle) urine samples. b) Partial Least Square – Discriminant
827 Analysis (PLS-DA) distribution plot of healthy (crosses and dark grey circle) and CKD (triangles

828 and faint grey circle) urine samples. c) Variable Importance in Projection (VIP) scores for the 25
829 most influential buckets of PLS-DA.

830

831 Supplement Table 1. Clinical data, serum and urine biochemistry of each dog included in the study.

832